Growth hormone is a key factor in body growth and organ development.
Its hypersecretion can result in overgrowth of body parts and enlargement of various organs. The consequences of this can result in complications associated with increased morbidity and mortality. One injection a month will allow effective biochemical control of the growth hormone hypersecretion, it will improve the clinical disorders associated with acromegaly and it will be convenient for the patient. Utilising a microsphere delivery system, this new drug provides a slow release of octreotide acetate from the site of injection and offers long-lasting control over the course of a month. Diagnosis of acromegaly can often be missed for up to 10 years because signs and symptoms develop gradually and because people do not seek treatment for the physical manifestations.